Pembrolizumab‐induced acquired perforating dermatosis
Abstract Immune checkpoint inhibitors such as the programmed cell death‐1 (PD‐1) inhibitors, pembrolizumab and nivolumab, are frontline treatments for several types of solid‐organ malignancies. However, cutaneous adverse effects with PD‐1 inhibitor therapy are common and include lichenoid reactions,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-12-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.462 |